Search Results - "Albiges, L."

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report by Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A.

Get full text

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma by Powles, T., Albiges, L., Bex, A., Grünwald, V., Porta, C., Procopio, G., Schmidinger, M., Suárez, C., de Velasco, G.

“…•This special article provides key recommendations on the immunotherapy treatments of renal cell carcinoma.•Recommendations are based on available scientific…”
Get full text

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) by Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J.S., Massard, C.

“…Androgen receptor (AR) signalling remains critically important in metastatic castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III…”
Get full text

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer by Derosa, L., Hellmann, M.D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A.J., Arbour, K.C., Chaft, J.E., Rouche, J.A., Zitvogel, L., Zalcman, G., Albiges, L., Escudier, B., Routy, B.

“…The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer…”
Get full text

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma by Izzedine, H., Derosa, L., Le Teuff, G., Albiges, L., Escudier, B.

“…To examine the association between hypertension (HTN), angiotensin system inhibitors (ASI) use and survival outcomes in patients with metastatic renal cell…”
Get full text

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma by Choueiri, T.K., Motzer, R.J., Rini, B.I., Haanen, J., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J.L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M.B., Pal, S.K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.

“…The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib…”
Get full text

TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma by Albiges, L., Barthélémy, P., Gross-Goupil, M., Negrier, S., Needle, M.N., Escudier, B.

“…Treatment with tivozanib, a highly selective and potent vascular endothelial growth factor receptor tyrosine kinase inhibitor, has demonstrated single-agent…”
Get full text

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus by Curigliano, G., Banerjee, S., Cervantes, A., Garassino, M.C., Garrido, P., Girard, N., Haanen, J., Jordan, K., Lordick, F., Machiels, J.P., Michielin, O., Peters, S., Tabernero, J., Douillard, J.Y., Pentheroudakis, G., Addeo, A., Albiges, L., Ascierto, P.A., Banerjee, S., Barlesi, F., Caldas, C., Cardoso, F., Cervantes, A., Chaberny, I.F., Cherny, N.I., Choueiri, T.K., Chua, M.L.K., Criscitiello, C., Curigliano, G., de Azambuja, E., De Ruysscher, D., de Vries, E., Dent, R., Douillard, J.Y., D’Ugo, D., Dziadziuszko, R., Faivre-Finn, C., Felip, E., Garassino, M., Garrido, P., Girard, N., Glynne-Jones, R., Golfinopoulos, V., Haanen, J., Hamilton, E., Jänne, P.A., Jordan, K., Kanesvaran, R., Kim, S.B., Liebert, U.G., Lordick, F., Machiels, J.P., Michielin, O., Mok, T.S.K., Morgan, G., Obermannova, R., Park, K., Passaro, A., Pentheroudakis, G., Peters, S., Reck, M., Salazar Soler, R., Scotté, F., Senan, S., Sessa, C., Smyth, E., Soo, R., Soria, J.C., Spicer, J., Strasser, F., Tabernero, J., Tan, D.S.W., Trapani, D., Van Cutsem, E., van Halteren, H., van Schil, P.E., Veronesi, G., Yang, J.

“…We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer…”
Get full text

Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre by Ruatta, F., Derosa, L., Escudier, B., Colomba, E., Guida, A., Baciarello, G., Loriot, Y., Fizazi, K., Albiges, L.

“…Bone metastases (BMs) are associated with significant morbidity and shorter survival in renal cell carcinoma (RCC). Our purpose was to identify prognostic…”
Get full text

Checkpoint inhibitors in metastatic papillary renal cell carcinoma by de Vries-Brilland, M., McDermott, D.F., Suárez, C., Powles, T., Gross-Goupil, M., Ravaud, A., Flippot, R., Escudier, B., Albigès, L.

“…•Papillary renal cell carcinoma (pRCC) is the most common non-clear cell renal cell carcinoma.•The treatment landscape of metastatic pRCC relied so far on…”
Get full text

PD-L1 expression in nonclear-cell renal cell carcinoma by Choueiri, T.K., Fay, A.P., Gray, K.P., Callea, M., Ho, T.H., Albiges, L., Bellmunt, J., Song, J., Carvo, I., Lampron, M., Stanton, M.L., Hodi, F.S., McDermott, D.F., Atkins, M.B., Freeman, G.J., Hirsch, M.S., Signoretti, S.

“…Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Formalin-fixed…”
Get full text

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Powles, T, Albiges, L, Bex, A, Comperat, E, Grünwald, V, Kanesvaran, R, Kitamura, H, McKay, R, Porta, C, Procopio, G, Schmidinger, M, Suarez, C, Teoh, J, de Velasco, G, Young, M, Gillessen, S

Get more information

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies by Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J.-M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., Colomba, E.

Get full text

Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers by Muller, M., Ferlicot, S., Guillaud‐Bataille, M., Le Teuff, G., Genestie, C., Deveaux, S., Slama, A., Poulalhon, N., Escudier, B., Albiges, L., Soufir, N., Avril, M.‐F., Gardie, B., Saldana, C., Allory, Y., Gimenez‐Roqueplo, A.‐P., Bressac‐de Paillerets, B., Richard, S., Benusiglio, P.R.

“…We addressed uncertainties regarding hereditary leiomyomatosis and renal cell carcinoma (HLRCC) by exploring all French cases, representing the largest series…”
Get full text

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma by Albiges, L., Chamming's, F., Duclos, B., Stern, M., Motzer, R.J., Ravaud, A., Camus, P.

“…The administration of mammalian target of rapamycin (mTOR) inhibitors can give rise to a potentially life-threatening adverse event, often referred to as…”
Get full text

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Kasper, B., Aamdal, S., Leahy, M.G., Rutkowski, P., Bauer, S., Gelderblom, H., Italiano, A., Lindner, L.H., Hennig, I., Strauss, S., Zakotnik, B., Anthoney, A., Albiges, L., Blay, J.-Y., Reichardt, P., Sufliarsky, J., van der Graaf, W.T.A., Debiec-Rychter, M., Sciot, R., Van Cann, T., Marréaud, S., Raveloarivahy, T., Collette, S., Stacchiotti, S.

“…Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene…”
Get full text

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study by Carneiro, F., Vinceneux, A., Larroquette, M., Rony, M., Carril, L., Laguerre, B., Blazevic, I., Bartelemy, P., Teyssonneau, D., Goujon, M., Linassier, C., Thiery-Vuillemin, A., Roubaud, G., Mourey, L., Albiges, L., Gravis, G., Gross-Goupil, M., Cancel, M.

“…Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable…”
Get full text

Prevalence and causes of burnout amongst oncology residents: A comprehensive nationwide cross-sectional study by Blanchard, P, Truchot, D, Albiges-Sauvin, L, Dewas, S, Pointreau, Y, Rodrigues, M, Xhaard, A, Loriot, Y, Giraud, P, Soria, J.C, Kantor, G

“…Abstract Background Burnout syndrome occurs frequently amongst oncology healthcare workers. It has a detrimental effect on the patient–physician relationship…”
Get full text

Severe COVID-19 in patients with hematological cancers presenting with viremia by Michot, J.M., Hueso, T., Ibrahimi, N., Pommeret, F., Willekens, C., Colomba, E., Francis, S., Bayle, A., Cournède, P.H., Merad, M., Foulon, S., Albiges, L., Gachot, B., Barlesi, F., Soria, J.C., Ribrag, V., Griscelli, F.

Get full text

TiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) by Barthelemy, P., Escudier, B., Ravaud, A., Negrier, S., Needle, M.N., Albiges, L.

Get full text